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HER2 (ERBB2) amplification is a driving oncogenic event in breast
cancer. Clinical trials have consistently shown the benefit of
HER2 inhibitors (HER2i) in treating patients with both local and ad-
vanced HER2+ breast cancer. Despite this benefit, their efficacy as
single agents is limited, unlike the robust responses to other receptor
tyrosine kinase inhibitors like EGFR inhibitors in EGFR-mutant lung
cancer. Interestingly, the lack of HER2i efficacy occurs despite suffi-
cient intracellular signaling shutdown following HER2i treatment.
Exploring possible intrinsic causes for this lack of response, we un-
covered remarkably depressed levels of NOXA, an endogenous in-
hibitor of the antiapoptotic MCL-1, in HER2-amplified breast cancer.
Upon investigation of the mechanism leading to low NOXA, we iden-
tified a micro-RNA encoded in an intron of HER2, termed miR-4728,
that targets the mRNA of the Estrogen Receptor α (ESR1). Reduced
ESR1 expression in turn prevents ERα-mediated transcription ofNOXA,
mitigating apoptosis following treatment with the HER2i lapatinib.
Importantly, resistance can be overcome with pharmacological inhibi-
tion of MCL-1. More generally, while many cancers like EGFR-mutant
lung cancer are driven by activated kinases that when drugged lead to
robust monotherapeutic responses, we demonstrate that the efficacy
of targeted therapies directed against oncogenes active through focal
amplification may be mitigated by coamplified genes.
NOXA | apoptosis | HER2 amplification | targeted therapies | MCL-1
inhibitor
Genetic amplification of the receptor tyrosine kinase (RTK)HER2 (ERBB2) is found in breast cancers with amplifica-
tion of the 17q12-21 locus, which occurs in 20–25% of invasive
breast cancers. It has been demonstrated that trastuzumab, a
humanized monoclonal antibody targeting HER2, when com-
bined with chemotherapy, significantly improves progression-
free survival (PFS) (7.4 vs. 4.6 mo) and overall survival (OS)
(25.1 vs. 20.3 mo) (1) in patients with HER2-amplified breast
cancer. A number of studies have since demonstrated that ad-
juvant use of HER2 kinase inhibitors, such as lapatinib, im-
proves outcomes in HER2-amplified breast cancers, including
reduced recurrence rates and increased OS (2). Interestingly,
despite these clear benefits, HER2 kinase inhibitors used as
monotherapy have demonstrated only minor benefit,
with objective response rates (ORRs) below 20% (3). In con-
trast, other RTK-driven cancers like EGFR-mutant lung cancers
(4) and ALK-translocated lung cancers (5) have ORRs approaching
60–70%.
Laboratory studies have indicated that EGFR, ALK, and
HER2 inhibitors have comparable ability to block the critical PI3K/
mTOR and MEK/ERK pathways (6, 7). This suggests that the
poorer response rates of HER2 inhibitor monotherapy relative to
those of EGFR and ALK inhibitors are not due to decreased in-
hibition of key intracellular signaling. Further downstream, these
pathways converge on the BCL-2 family of proteins, which govern the
ability of the cell to undergo apoptosis (8). The degree of apoptosis
induced by targeted therapies is critical and directly influences tar-
geted therapy responses (9–15). For instance, in response to MEK/
ERK pathway inhibition, all three of these RTK-driven cancer sub-
types up-regulate the expression of the proapoptotic, BH3-only BCL-
2 family member, BIM. Loss of BIM expression universally protects
these cancers from kinase inhibitor-induced apoptosis (6, 9, 14).
Interestingly, it is now appreciated that cancers with lower
basal expression of functional BIM, either due to genetic poly-
morphisms (12) or other less defined causes (9, 11), are deficient
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in an apoptotic response following kinase inhibitor treatment,
even in the presence of MEK/ERK (and PI3K/mTOR) signal
shutdown. Clinical studies have now been designed to overcome
these BIM-centric deficiencies, by adding apoptosis-inducing
agents to sensitize cancers to kinase inhibitors (16, 17).
In our investigations, we made the unexpected discovery that
levels of NOXA (encoded by PMAIP1) were markedly low in breast
cancers. We subsequently found that this phenomenon is strongly
enriched inHER2-amplified breast cancers. As NOXA acts primarily
as an endogenous inhibitor of the antiapoptotic BCL-2 family
member MCL-1, we hypothesized that NOXA deficiency serves as
a universal apoptotic block in HER2-amplified breast cancers,
which could explain the lack of clinical HER2 inhibitor mono-
therapy activity. In this work, we tested this hypothesis and in-
vestigated the cellular mechanism(s) underlying this phenomenon.
Results
NOXA Is Uniformly Suppressed in HER2-Amplified Breast Cancer.Using
gene expression datasets of cancer cell lines to understand the
landscape of BCL-2 family member expression in breast cancer,
we found that, within the cancer cell line encyclopedia (CCLE),
levels of mRNA encoding the proapoptotic protein NOXA
(PMAIP1) were markedly reduced in breast cancer cells compared
with other cancer cell subtypes (Fig. S1) (18). Parsing multi-
ple datasets (19–25) in the Oncomine database (26) and the
R2 genomics application (r2.amc.nl), we found that NOXA
mRNA levels were remarkably and specifically depressed in the
HER2-amplified subset of breast cancer (Fig. 1A), while mRNA
levels of other major proapoptotic BCL-2 family members were
not depressed (Fig. S2A). We also found an inverse correlation
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Fig. 1. NOXA (encoded by PMAIP1) is uniformly suppressed in HER2-amplified breast cancer. (A) Scatter plots comparing PMAIP1 mRNA levels in HER2-
amplified versus non-HER2–amplified breast cancers from six tumor databases of breast cancers obtained from Oncomine (https://www.oncomine.com/
resource/login.html, May 2017, Thermo Fisher Scientific) (TCGA dataset: HER2−, n = 194; HER2+, n = 67; Bonnefoi dataset: HER2−, n = 83; HER2+, n = 29;
Kao dataset: HER2−, n = 252; HER2+, n = 75; Lu dataset: HER2−, n = 69; HER2+, n = 26; Richardson dataset: HER2−, n = 29; HER2+, n = 8; Chin dataset:
HER2−, n = 71; HER2+, n = 8). Red lines represent means. Error bars indicate ± SEM. (B) Scatter plots of PMAIP1 mRNA expression against HER2 mRNA
expression from three datasets obtained from the R2 genomics application (r2.amc.nl) (Black dataset: n = 107; Sotiriou dataset: n = 120; Iglehart dataset:
n = 123). (C ) HER2 (ERBB2) and NOXA (PMAIP1) mRNA expression correlation from 1,102 breast cancer tumors from TCGA. Red box indicates NOXA levels
of high HER2 cancers. Yellow box indicates HER2 mRNA levels of tumors that have higher NOXA mRNA levels. P value was calculated using the Mann–
Whitney U test (with P values < 0.05 equaling significance). (D) Untreated cells from a panel of HER2-amplified and TNBC cell lines were lysed and
separated by SDS/PAGE, subjected to immunoblotting, and probed for HER2 or NOXA. GAPDH was used as a loading control.

















between HER2 and NOXA mRNAs in breast cancer (Fig. 1B).
Consistently, from 1,102 breast cancer specimens deposited in The
Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/),
we found a striking relationship between the highest HER2-
expressing tumors and low NOXA expression (Fig. 1C). On the
other hand, our analysis did not indicate a statistically significant
relationship between MCL1 and HER2 mRNA (Fig. S2D). Fur-
thermore, breast cancers determined to be HER2-positive (HER2+)
by protein overexpression as measured by immunohistochemistry
had significantly lower NOXA levels (Fig. S2B).
We next performed laboratory-based experiments to confirm
the low levels of NOXA in HER2-amplified breast cancer and to
understand the biological consequences of this deficiency. We first
wanted to confirm that the mRNA expression results from the cell
line and tumor datasets were reflected at the protein level. To
investigate the expression levels of NOXA protein in HER2-
amplified breast cancers, we interrogated whole-cell lysates from
a panel of HER2-amplified and triple-negative breast cancer
(TNBC) cell lines that were otherwise randomly selected. Con-
sistently, the HER2-amplified breast cancer cell lines had mark-
edly lower NOXA levels compared with the TNBC cell lines (Fig.
1D). Interestingly, BT-474 and MDA-MB-361 (HER2+)/(ER+)
cell lines (27), which have elevated ERα protein levels among the
HER2+ cell lines (Fig. S2C), demonstrated higher NOXA levels
than the (HER2+)/(ER−) lines but lower levels than the TNBC
cell lines. In contrast to NOXA, the key antiapoptotic proteins
MCL-1 and BCL-xL did not exhibit expression patterns associated
with HER2 status (Fig. S2C). Of note, while MCL-1 and BCL-xL
were both expressed similarly inHER2-amplified and TNBC cell lines,
the antiapoptotic protein BCL-2 was lower in mostHER2-amplified
cell lines (Fig. S2C), consistent with the mRNA data (Fig. S2A).
ER Status Affects NOXA Levels. To investigate whether ER status
also impacted NOXA levels, we interrogated TCGA breast tu-
mors in the Oncomine database (26). The lowest levels of NOXA
mRNA expression were observed in the ER−/HER2+ subset of
tumors, implying an association between both HER2 and NOXA
and ER and NOXA (Fig. 2A). Consistently, within HER2-ampli-
fied breast cancers, ER− breast cancers had substantially lower
levels of NOXA than ER+ breast cancers (Fig. 2A). These data
indicate that both HER2 status and ER status correlate with
NOXA levels. ER has been reported to directly up-regulate NOXA
mRNA levels (28). In a different set of ER+ breast cancers (29),
ER+ breast cancers demonstrated markedly higher NOXA levels
compared with ER− tumors (Fig. 2B). In addition, when 22
HER2+ and 88 luminal A subtype breast cancers (29) [the latter are
typically ER+/HER2− (30)] were compared, there was a striking
difference in NOXA expression (Fig. 2C) (29). To determine
whether there is also functional evidence to support these find-
ings, we analyzed gene expression data from a clinical trial of
presurgical treatment with the aromatase inhibitor letrozole,
which suppresses estrogen biosynthesis to inhibit ER (31).
Strikingly, NOXA was among the most significantly altered
genes, markedly down-regulated after 14 d of letrozole treatment




























































































Fig. 2. NOXAmRNAexpression is correlatedwith both ERα andHER2 in breast cancer. (A) Scatter plots comparing PMAIP1mRNA levels inHER2−/ER+, HER2+/ER−, ER−/HER2−,
and ER+/HER2+ breast cancer tumors available for analysis from the TCGA obtained from Oncomine (https://www.oncomine.com/resource/login.html, May 2017, Thermo Fisher
Scientific). Red lines representmeans. The P valueswere calculated using theMann–WhitneyU test. (HER2−/ER+,n= 126; HER2+/ER−,n= 14; ER−/HER2−,n= 49; and ER+/HER2+,
n = 46.) Error bars are SEM. (B) Box plot demonstrating differential PMAIP1 mRNA expression levels between ER− (n = 113) and ER+ (n = 150) [as determined by immuno-
histochemistry (IHC)] breast cancers (29). P value was obtained from one-way ANOVA test. (C) Box plot demonstrating differential PMAIP1 mRNA expression levels between
HER2+ (n = 22) and luminal A breast cancers (n = 88). P value was obtained from one-way ANOVA test. (D) Box plot showing expression alteration (by fold change) of NOXA
mRNA in ER+ breast tumor samples from 58 patients obtained at baseline and 14 d after presurgical treatment with letrozole (2.5 mg/d) (31).
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(Fig. 2D). These data support the notion that ER drives NOXA
expression in breast cancer.
Coamplification of miR-4728 in HER2-Amplified Breast Cancer Leads
to ER-Mediated Down-Regulation of NOXA. Our previous data
showed a striking inverse relationship between HER2 and NOXA
(Figs. 1 and 2 A and C). To gain insights into the mechanism that
leads to NOXA deficiency in HER2-amplified breast cancers, we
introduced siRNA targeting HER2 in three HER2-amplified
breast cancer cell lines. Surprisingly, silencing HER2 did not affect
NOXAmRNA levels (Fig. S3A). To further investigate a potential
causative link between HER2 and NOXA, we analyzed the pro-
tein levels of NOXA in isogenic breast cancer cell lines with low
(endogenous) vs. high (exogenous cDNA) HER2 (MCF7-GFP vs.
MCF7-HER2) (32). Consistent with the siRNA analysis, we did
not find that HER2 overexpression altered NOXA levels (Fig.
S3B). We conclude that the expression of NOXA is independent
of HER2 signaling. However, evidence in Figs. 1 and 2 suggested
that NOXA expression is dependent on HER2 amplification and
HER2 expression; thus, there seems to be a contradiction.
We then investigated what would explain this seeming con-
tradiction. Another potential mechanism by which NOXA may
be down-regulated is through expression of micro-RNAs (miRNAs)
that target the gene. Analyzing TCGA data from 964 tumors,
we found that the top correlating miRNA with HER2 mRNA,
out of 1,626 miRNAs, is miR-4728, with a correlation coeffi-
cient of 0.7465 (Fig. 3A). These data led us to focus on miR-
4728, which interestingly is located within intron 23 of the
HER2 gene and, as such, could be processed from the same
primary transcript (33). Two mature miRNAs are formed from
the precursor miR-4728—miR-4728-5p and miR-4728-3p—with
miR-4728-3p being more prominently expressed as a mature
miRNA (34). As previously mentioned, HER2 drives breast cancer
formation as a focal amplicon manifesting as 17q12-21 amplification
(35). An example of the amplicon in a HER2-amplified breast
cancer from TCGA is depicted in Fig. S4A, illustrating the coam-
plification of miR-4728. Consistently, we found that the expression
levels of miR-4728-3p in our panel of HER2-amplified breast can-
cers are much higher compared with the TNBC cell lines (Fig. 3B).
Importantly, it has recently been reported that miR-4728 tar-
gets ERα (ESR1) mRNA (36, 37) and that ERα can function as a
transcriptional factor for NOXA (28). Indeed, selective in-
hibition of ERα in BT-474 and MDA-MB-361 cells resulted in
down-regulation of NOXA (Fig. S4B). Furthermore, our analy-
ses indicated an inverse correlation between ER mRNA and miR-
4728, which became apparent when we separated breast tumors
by miR-4728 expression: The highest miR-4728 expressors had
markedly low ER mRNA (Fig. 3C) as well as NOXA mRNA (Fig.
3D). We therefore hypothesized that when HER2 is amplified in














































































Fig. 3. miR-4728 is coamplified and strongly correlated with HER2, whileNOXA (PMAIP1) and ERα (ESR1) are inversely correlatedwithmiR-4728-3p in breast cancer.
(A) HER2 (ERBB2) andmiR-4728 (hsa-miR-4728) correlation over 964 breast cancer tumors from TCGA. The Spearman correlation coefficient (r) and the P value (using
Mann–Whitney U test) were calculated. (B) Total RNA enriched with small RNAs was isolated from a panel of HER2-amplified and TNBC cell lines. MiRNAs were
reverse-transcribed using a TaqMan miRNA assay and finally analyzed by qPCR. miR-26a-5p was used as an endogenous control, and the data were expressed as a
relative value to the cell line expressing the highest levels ofmiR-4728-3p (UACC-893); n = 3; error bars are ±SD. (C) Scatter plots comparing the ESR1mRNA levels in
the top 5% miR-4728 expressors versus the next 5% miR-4728 expressors versus the lowest 90% miR-4728 expressors from data analyses of 964 breast tumor
samples. (D) Scatter plots comparing the PMAIP1 (NOXA) mRNA levels in the top 5%miR-4728 expressors versus the next 5%miR-4728 expressors versus the lowest
90% miR-4728 expressors from data analyses of 964 breast tumor samples. For (C) and (D), the red lines are means and the error bars are ± SEM.

















of ER and NOXA, resulting in a mitigated response to HER2
inhibitors through the MCL-1 function.
We inhibited miR-4728-3p after transfection of MD-MB-361 and
BT-474 cells with a specific pLV-hsa-miR-4728-3p locker plasmid
or a scrambled vector control (38). As demonstrated in Fig. 4A, we
observed a concomitant increase of estrogen receptor α (ERα), the
dominant ER isoform in breast cancer (39), and of NOXA. Of note,
the phosphorylation status of ERK served as a positive control for
miR-4728 inhibition (38). In contrast, overexpression of miR-4728-3p
in T47D (HER2−/ER+) and BT-474 (HER2+/ER+) cells was
sufficient to decrease both ERα and NOXA (Fig. 4B). The increased
expression levels ofmiR-4728-3p, in our overexpression models, were
verified by qPCR analysis (Fig. S4C). Moreover, inhibition of ERα
with a selective antagonist (fulvestrant) (40) mitigated the effect of
pLV-hsa-miR-4728-3p locker plasmid on NOXA induction inMDA-
MB-361 cells (Fig. 4C). We then tested whether inhibition of miR-
4728 sensitizes HER2-amplified breast cancer cells to the HER2
inhibitor, lapatinib. Indeed, MDA-MB-361 as well as BT-474 cells
transfected with the pLV-hsa-miR-4728-3p locker plasmid demon-



















































































































































































































Fig. 4. Coamplification of miR-4728 in HER2-amplified breast cancer causes ERα-mediated NOXA down-regulation and its inhibition sensitizes them to
lapatinib, while its overexpression rescues lapatinib-treated HER2-amplified breast cancer cells from apoptosis. (A) The indicated HER2-amplified breast cancer
cell lines were transfected with the pLV-hsa-miR-4728-3p locker plasmid (miR-4728 inhibitor) or control plasmid expressing a scrambled sequence (vector
control), and the corresponding lysates were subjected to immunoblotting for NOXA, ERα, HER2, and phospho-ERK. GAPDH and β-ACTIN were used as
loading controls. (B) The indicated breast cancer cell lines were infected with control vector or a mir-4728 overexpressing construct, and the corresponding
lysates were subjected to Western blotting and probed for NOXA, ERα, HER2, and β-ACTIN (loading control). (C) MDA-MB-361 cells were transfected with the
appropriate constructs, as in A, treated with no drug or 200 nM fulvestrant for 24 h and probed for the indicated proteins. β-ACTIN was used as a loading
control. (D) MDA-MB-361 cells were transfected as in A and treated with no drug and with 1 μM of lapatinib for the indicated time points. The corresponding
lysates were subjected to Western blotting and probed for the indicated proteins. β-ACTIN was used as a loading control. (E) BT-474 cells were transfected
with the pLV-hsa-miR-4728-3p locker plasmid (miR-4728 inhibitor) or control plasmid expressing a scrambled sequence (vector control), treated with no drug
or 1 μM lapatinib for 24 h. The corresponding lysates were subjected to Western blotting and probed for the indicated proteins. β-ACTIN was used as a loading
control. BT-474 cells were also infected with control vector or a miR-4728–overexpressing construct, like in B, and treated with no drug or 1 μM lapatinib for
36 h. The corresponding lysates were subjected to Western blotting and probed for the indicated proteins. (F) Suggested model for NOXA regulation by the
HER2 amplicon in breast cancer.miR-4728-3p is coamplified with its host gene (HER2) and proceeds to silence ESR1 expression. ERα encoded by ESR1 functions
as a transcriptional factor of NOXA; therefore, miR-4728 coamplification leads to down-regulation of NOXA (“No Rx”: No drug).
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cells (Fig. 4 D and E), while overexpression of miR-4728 in BT-
474 cells rescued lapatinib-treated cells from apoptosis (Fig.
4E). Altogether, these data demonstrate that miR-4728 coam-
plification results in ER silencing, which in turn prevents ex-
pression of NOXA (28). Our model is depicted in Fig. 4F.
Pharmacological Inhibition of MCL-1 Sensitizes HER2-Amplified Breast
Cancer Cells to Lapatinib. Altogether, our data indicate that coam-
plification of miR-4728 plays a heretofore undiscovered role in
17q12-21 amplified breast cancer and that deficient expression of
the intrinsic MCL-1 inhibitor NOXA may lead to an underlying
apoptotic block in HER2-amplified breast cancers. To determine
whether NOXA expression confers sensitivity to HER2 inhibition,
we first artificially increased the levels of NOXA by transducing
viral particles containing a NOXA-expressing plasmid into HER2-
amplified breast cancer cells, treating the cells with a time course
of lapatinib (Fig. 5A). Consistent with our hypothesis, NOXA-
expressing cells were markedly sensitized to lapatinib, compared
with control cells, as evidenced by increased PARP cleavage in HCC-
































































































































































































































































































































































































































































































































































































































Fig. 5. S63845 sensitizes HER2-amplified breast cancer cells to lapatinib. Proapoptotic BCL-2 proteins BIM and BAK are required for the function of S63845,
which selectively displaces BIM and BAK fromMCL-1. (A) HCC-1419 andMDA-MB-453 cells were transduced with lentivirus containing an empty vector or a NOXA-
expressing plasmid and treated with no drug or 1 μM lapatinib for 6, 12, and 24 h. Whole-cell lysates were prepared and subjected to Western blotting and
probed for cleaved PARP, NOXA, and GAPDH. (B) A panel of HER2-amplified breast cancer cell lines were treated with lapatinib with or without 1 μM S63845 for
3 h (SKBR3, BT-474, and UACC-893) or for 8 h (MDA-MB-453, HCC-1419, and EFM-192A), and the expression levels of cleaved PARP were detected by Western
blotting. (C) The stable cell lines described in D were treated with 50 nM scrambled or BIM-targeting siRNA for 24 h. Cells were reseeded and treated the following
day with no drug, 1 μM lapatinib, 1 μM S63845, and their combination overnight. Cell lysates were prepared and subjected to Western blotting and probed for
cleaved PARP, BAK, phospho-HER2, MCL-1, BIM, and GAPDH. (D) HCC-1419 and MDA-MB-453 cells were treated with no drug, 1 μM lapatinib, 10 μM A1210477,
1 μM S63845, and their combinations (A1210477/lapatinib and S63845/lapatinib) overnight, and CHAPS lysates were prepared and subjected to AB-1 IP and
Western blotting. Total cell lysates were analyzed in parallel. (E) MCL-1 complexes were immunoprecipitated from the indicated HER2-amplified breast cancer cell
lines following overnight treatment with no drug, lapatinib, S63845, and their combination at the indicated drug concentrations. An IgG-matched isotype an-
tibody was served as an immunoprecipitation control. The interaction between MCL-1 and BIM/BAK proteins was investigated (“No Rx”: No drug).

















MDA-MB-361 cells (Fig. S5A). Immunoprecipitation analysis of
these lysates revealed that MCL-1:BIM and MCL-1:BAK com-
plexes were reduced by NOXA overexpression, consistent with the
understanding of NOXA as an endogenous MCL-1 inhibitor (41)
(Fig. S5 B and C). To further confirm this effect of NOXA ex-
pression, we reduced MCL-1 expression with a siRNA targeting
MCL-1 (15) or a siRNA with a scrambled sequence and treated
HER2-amplified HCC-1419 and MDA-MB-453 breast cancer cells
with lapatinib. As expected, we found that the cells treated with
siRNA targeting MCL-1 were markedly sensitized to lapatinib
compared with the scramble siRNA-treated cells (Fig. S5D).
These data indicate that NOXA overexpression confers sensitivity
to HER2 inhibitors in HER2-amplified breast cancers.
Due to the emerging role of MCL-1 in cancer development,
progression, and cell survival (42), MCL-1 inhibitors are being heavily
pursued as anticancer agents. A1210477 is a BH3 mimetic that has
been described to bind with high affinity to MCL-1 and selectively
disrupts the interaction between proapoptotic BIM and MCL-1 (43).
We therefore tested A1210477 in combination with lapatinib. Our
data revealed that the addition of A1210477 effectively reduced the
apoptotic threshold and markedly sensitized HER2-amplified breast
cancer cells to lapatinib, as evidenced by cleaved PARP induction
(Fig. S6A). The increased amount of apoptosis from the combination
of lapatinib and A1210477 translated to enhanced sensitivity in 72-h
cell viability assays (Fig. S6B). To further confirm the mode of activity
of A1210477, we treated additional HER2-amplified breast cancer
cell lines with lapatinib, A1210477, or the combination and evaluated
the status of the major intracellular signaling pathways downstream
of HER2 (6, 44). As expected, A1210477 did not alter the PI3K/
mTOR or MEK/ERK pathways (Fig. S7), indicating that its sensi-
tizing effects were specific to MCL-1 inhibition.
To better understand the mechanism linking sensitization
of the HER2-amplified breast cancer cells to A1210477, we
immunoprecipitated MCL-1 complexes in HCC-1419 and MDA-
MB-453 cells. As expected, addition of A1210477 disrupted the
interaction between MCL-1 and BIM (45) (Fig. S8A), releasing
BIM to activate the effector molecules BAX and BAK and in-
duce apoptosis (46–50). Furthermore, it is worth noting that
lapatinib and A1210477 increased BIM and MCL-1 levels, re-
spectively, consistent with previous reports (43, 51). The conse-
quence of these increases was, at least in part, the accumulation of
MCL-1:BAK complexes (Fig. S8A). To further study the roles of
BIM and BAK in lapatinib/A1210477-mediated apoptosis, we stably
knocked down BAK (shBAK) in the same HER2-amplified breast
cancer cell lines (HCC-1419 and MDA-MB-453) and silenced BIM
with siRNA. In both cell lines, there was a clear requirement for
both BIM and BAK in lapatinib/A1210477-mediated cell death,
with the HCC-1419 cells particularly reliant on BAK (Fig. S8B).
The MCL-1 Inhibitor S63845 Synergizes with Lapatinib by Disrupting
both MCL-1:BAK and MCL-1:BIM Complexes in HER2-Amplified Breast
Cancers. The addition of A1210477 to lapatinib appeared effec-
tive because low NOXA caused the increase in MCL-1:BIM
complexes, and A1210477 disrupted these complexes, therefore
increasing the amount of liberated BIM. This is a critical step in
apoptosis caused by kinase inhibitors and BCL-2 family inhibitors
(8, 9, 15, 52–55). However, A1210477 did not robustly disrupt
MCL-1:BAK complex formation (Fig. S8A). The new selective
MCL-1 inhibitor, S63845, reportedly disrupts both BIM:MCL-1
and BAK:MCL-1 complexes (45), which may be a result of higher
affinity for binding to the MCL-1 hydrophobic pocket than
A1210477 (56). We first combined lapatinib with S63845 and
found that the combination potently induced apoptosis as evi-
denced by cleaved PARP (Fig. 5B) and FACS analysis of annexin
V-stained cells (Fig. S9A). Additionally, the combined treatment
reduced viable cell numbers in HER2-amplified breast cancer cells
(Fig. S9B). Intriguingly, in some of the cell lines (BT-474 and
UACC-893), the combination of the two drugs displayed remarkable
synergism, leading to robust cell death in less than 24 h (Fig. 5B
and Fig. S9B). To ensure that S63845 functions exclusively through
MCL-1 inhibition, we immunoprecipitated BIM complexes in both
BT-474 and UACC-893 cells and found that addition of S63845
disrupts only the BIM:MCL-1 and not the BIM:BCL-xL or the
BIM:BCL-2 complex (Fig. S10A). As in the case of A1210477,
S63845 leaves PI3K/mTOR and MEK/ERK signaling unperturbed
(Fig. S10B), confirming previously published data (57).
We next examined the requirement for BIM and BAK in
lapatinib-, S63845-, and S63845/lapatinib-mediated toxicity in
the HER2-amplified HCC1419 and MDA-MB-453 cells. Similar
to the data with A1210477, knockdown of both BIM and BAK
substantially mitigated drug-induced toxicity in the cells, with
knockdown of BAK alone markedly protecting HCC1419 cells
(Fig. 5C). Consistently, knockdown of BAK and BIM translated
to significantly increased cell viability following treatment com-
pared with controls (Fig. S11A). We next investigated any in-
volvement of BAX in drug-induced toxicity. Knockdown of BAX
expression with shBAX also protected cells from MCL-1i/
lapatinib-induced toxicity, albeit to a lesser degree than BAK
(Fig. S11B). Interestingly, the protective effects of BAX and
BIM appear redundant, as knockdown of BIM in the presence of
knockdown of BAX did not markedly increase the amount of pro-
tection in either cell line (Fig. S11B). Using specific antibodies that
recognize the active conformation of BAK or BAX (clone AB-1 for
BAK or clone 6A7 for BAX, respectively) (58, 59), we immuno-
precipitated lysates from HCC-1419 and MDA-MB-453 cells treated
overnight and individually with lapatinib, A1210477, and S63845 or
the combinations of lapatinib/A1210477 and lapatinib/S63845, with
the AB-1 and 6A7 antibodies. Consistently, we detected levels of
both active BAK and BAX following drug exposure that were gen-
erally much more pronounced in the combination treatments com-
pared with single agents (Fig. 5D and Fig. S11C).
To verify that both MCL-1:BIM and MCL-1:BAK complexes
were disrupted by S63845, we immunoprecipitated MCL-1 com-
plexes in lysates of the HER2-amplified breast cancer cells, HCC-
1419 and MDA-MB-453, following treatment with lapatinib, S63845
(at two concentrations of 300 nM and 1 μM), or their combination
(Fig. 5E). Immunoprecipitation complex investigation confirmed that
both MCL-1:BIM and MCL-1:BAK complexes were disrupted fol-
lowing treatment with 1 μM of S63845. These data imply that
S63845-induced apoptosis involves disruption of BIM:MCL-1 and
BAK:MCL-1 complexes in HER2-amplified breast cancer cells.
We next analyzed lysates from these HER2-amplified breast can-
cer cells to assess dependence upon the three main antiapoptotic
BCL-2 family proteins for survival, following HER2 inhibition.
Treatment with the combination of lapatinib/S63845 led to a marked
increase in PARP cleavage, compared with lapatinib/A1331852 (a
BCL-xL inhibitor) or lapatinib/venetoclax (a BCL-2 inhibitor) (Fig.
S12A). However, knocking down BAK inHCC-1419 andMDA-MB-
453 cells conferred resistance to MCL-1 inhibition (Fig. S12B).
Combination Treatment with Lapatinib and S63845 Consistently
Induces Tumor Regression. To expand and corroborate our find-
ings in vivo, BT-474 xenografts were established in NOD SCID
gamma (NSG) female mice, and mice were treated with 100 mg/
kg of lapatinib, 25 mg/kg of S63845, or their combination, for
5 consecutive days as previously described (60). Both drugs
showed modest efficacy as single agents and variably slowed
tumor growth or induced modest regression. However, the
combination led to marked regression of 10/10 tumors (Fig. 6A
and Fig. S13A). Cleaved PARP was up-regulated following
combination drug treatment (Fig. 6B), indicating cell death.
Furthermore, we assessed the drug treatments in a HER2+/ER−
breast cancer patient-derived xenograft (PDX) model via in-
jection into NSG mice following the same dosing schedule.
Again, the single agents displayed modest activity, inhibiting tu-
mor growth, whereas the combination shrank most of the tumors,
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similar to the BT-474 xenograft model (Fig. 6C and Fig. S13B).
Immunohistochemistry detection of cleaved caspase-3 confirmed
induction of apoptosis in a PDX tumor treated with S63845, with
more pronounced apoptosis seen with the combination (Fig.
S13C), consistent with the in vitro data (Fig. 5). Altogether, these
data indicate that the miR-4728–ERα–NOXA pathway can be
successfully targeted by cotreatment of HER2 inhibitors together
with MCL-1 inhibitors.
Discussion
Breast cancers with amplification of 17q12-21 are driven by, and
addicted to, HER2 (60). In genetically engineered mice, HER2
expression driven by the MMTV promoter is sufficient to cause
the development of multiple invasive mammary carcinomas, and
tumor regressions follow inactivation of MMTV-HER2 in these
mice (61). Follow-up studies in these mouse models focused on
the proapoptotic BH3-only protein BIM, the abundance of
which was increased upon HER2 inhibition. When HER2 was
inactivated in MMTV-HER2 mice crossed with BIM−/− knockout
mice, tumors did not regress upon MMTV-HER2 inactivation
(14). These studies elegantly demonstrated the importance of a
BCL-2 family member-mediated apoptotic response upon HER2
inhibition in HER2-amplified breast cancer.
Clinically, despite their clear benefit in the adjuvant setting
(62), HER2 inhibitors have shown only modest activity as single
agents (63). This is somewhat surprising given that RTK-addicted
cancers in other solid tumor types are effectively treated with RTK
inhibitor monotherapies (4, 64, 65). Given the demonstrated role of
apoptosis in targeted therapy efficacy (reviewed in ref. 8), we rea-
soned that there may be a widespread deficiency in the HER2
inhibitor-induced apoptotic response.
Surprisingly, we uncovered that coamplification of the HER2
intronic miRNA, miR-4728, is responsible for depressed NOXA
expression. We demonstrated that while blocking miR-4728 in-
creases phosphorylation and activation of ERK, as previously
demonstrated (38), it also leads to up-regulation of ER and
NOXA. Thus, our data point to a dual role for miR-4728: as a
tumor antagonistic gene through down-regulation of pERK (38)
and as an antagonist of HER2 inhibitor therapy by suppression
of NOXA. Importantly, since HER2 inhibitors like lapatinib
block ERK signaling in HER2-amplified breast cancers (Figs. 4
D and E and 5 and Figs. S6A, S8B, S11B, and S12, and ref. 9),
it is likely that miR-4728 only has an antagonistic effect in the
presence of HER2 inhibitors, while miR-4728 likely promotes
tumorigenesis in the absence of HER2 inhibition. Indeed, we





















































Fig. 6. Combination treatment with lapatinib and S63845 leads to antitumor activity in vivo. (A) Approximately 15 × 106 BT-474 cells were injected
orthotopically into each NSG mouse (both sides) and monitored for subsequent growth. After tumors reached a size of ∼150 mm3, mice were treated with
25 mg/kg S63845, 100 mg/kg lapatinib, or the combination for 5 consecutive days. Tumor measurements were performed every day by calipers, and the
percentage (%) of changes in volume for each tumor is shown by a waterfall plot (control, 6 tumors; lapatinib, 6 tumors; S63845, 9 tumors; combination,
10 tumors). P values were calculated using the Student t test. (B) Tumors were harvested from BT-474 tumor-bearing mice ∼2 h after lapatinib administration,
and tumor lysates were subjected to Western blot analyses and probed for cleaved PARP and GAPDH (“No Rx”: No drug). (C) Approximately 1.5 × 106 cells
derived from a PDX breast cancer model were injected orthotopically into each NSG mouse (both sides) and monitored for subsequent growth. After tumors
reached a size of 150–200 mm3, mice were treated with 25 mg/kg S63845, 100 mg/kg lapatinib, or the combination for 5 consecutive days. Tumor mea-
surements were performed every day by calipers, and the percentage (%) of changes in volume for each tumor is shown by a waterfall plot (control, 8 tumors;
lapatinib, 7 tumors; S63845, 9 tumors; combination, 11 tumors). P values were calculated using the Student t test.

















in the lack of responses to HER2 inhibitors (Fig. 4). Moreover,
the lack of single agent efficacy of HER2-targeting therapeutic
antibodies, like trastuzumab (Herceptin) (66), might also be
at least partly explained by down-regulation of NOXA ex-
pression. However, since trastuzumab-mediated cytotoxicity in-
cludes function outside of HER2 pathway inhibition (67, 68), the
relationship between deficient NOXA and trastuzumab efficacy
may differ. Importantly, however, Merino et al. (57) demon-
strated robust activity of trastuzumab and S63845 in a HER2-
amplified PDX model.
More globally, these data reveal that for kinases activated by
focal amplification and treated with therapies targeting that ki-
nase, a thorough understanding of coamplified genes may inform
treatment strategies. In this case, amplification of miR-4728 in-
forms that HER2-amplified breast cancers should be treated with
a HER2 inhibitor and a MCL-1 inhibitor. This may be particu-
larly relevant for patients with high HER2 copy number as well
as HER2+/ER− patients that have the lowest levels of NOXA
(Fig. 2A).
Direct MCL-1 inhibitors are now being developed, reflecting
the growing understanding of the importance of MCL-1 in can-
cer. A1210477 was the first widely tested, specific MCL-1 in-
hibitor. Underlying the emerging importance of MCL-1 in breast
cancer, Xiao et al. (53) demonstrated that A1210477 has single-
agent activity in a subset of breast cancers, including HER2-
amplified breast cancer cell lines. Similar to our findings, the
disruption of MCL-1:BIM complexes was reported as a major
mechanism of A1210477 efficacy, and BIM reduction by siRNA
markedly mitigated the efficacy of the agent. They also noted
that MCL-1 increased in whole-cell lysates of SKBR3 cells fol-
lowing A1210477 treatment, similar to our findings (Fig. S8A).
Moreover, they observed an increase in MCL-1:BAK complexes
at lower concentrations (2.5 μM) of A1210477. Since it is already
known that MCL-1 has a preference for binding to BAK over
BAX (69), the disruption of MCL-1:BAK complexes is of sig-
nificant importance for the induction of apoptosis, which we
achieved with S63845 (Fig. 5E) and could explain why we saw a
larger amount of BAK activation after treatment with S63845
vs. A1210477 (Fig. 5D).
Both selective MCL-1 inhibitors used in our study function as
derepressors by displacing proapoptotic BCL-2 family proteins
from MCL-1. They both increase MCL-1 levels, likely by inhib-
iting the interaction of MCL-1 with proteins such as NOXA that
facilitate proteasomal degradation (43, 56). Over the last 10 y,
several models have been developed to investigate the de-
pendence of different types of cancer on the antiapoptotic BCL-2
family proteins for survival (70). Our data support that the ob-
served sensitivity of HER2-amplified breast cancer cell lines to
MCL-1 inhibition in the presence of lapatinib was BIM-, BAK-,
but also BAX-dependent, since silencing these three proa-
poptotic BCL-2 family members significantly rescued the cells
from apoptosis. It should be noted that BIM knockdown and
BAX knockdown seemed redundant (Fig. S11B), consistent with
BIM preferentially activating BAX to kill (49, 71). Our data,
therefore, highlight the importance of both displacement of BIM
from the prosurvival BCL-2 family proteins (to activate BAX)
and displacement of BAK from MCL-1.
While this manuscript was in preparation, Merino et al. (57)
demonstrated that S63845 and the HER2-directed antibody tras-
tuzumab combined to induce marked antitumor activity in HER2-
amplified breast cancer. Their treatment schedule differed from
ours: Merino et al. treated mice once a week with S63845, dem-
onstrating that long-term use of the combination (60 d) is both
tolerable and efficacious. Our data also support the use of this
combination in vivo (Fig. 6 and Fig. S13), and the sum of our work
provides a mechanistic rationale for its implementation. Further-
more, as we found that NOXA (PMAIP1) mRNA levels are lowest
in the HER2-amplified/ER− subgroup of human breast tumors
(Fig. 2A), this subgroup of patients may benefit the most from
combined targeting of HER2 and MCL-1. These findings may
have further implications, as we also report NOXA was among the
most highly down-regulated genes following treatment of ER+
breast cancers with the antiaromatase letrozole (Fig. 2D), which
we recapitulated in vitro (Fig. S4B). These data suggest these
breast cancers may also acquire a reliance on MCL-1 as treatment
progresses with antiestrogen drugs, and our future work will focus
on delineating this precise point.
Overall, our study uncovers an important role for an amplified
miRNA within the 17q12-21 amplicon, driving resistance to
HER2 inhibitors. This study represents an example of a coam-
plified gene that mitigates response to a kinase inhibitor within
the same amplicon that created the kinase addiction in the first place.
It also highlights difficulties that may arise when targeting an oncogene
within a cancer-addicted amplicon with a targeted therapeutic—dif-
ficulties that do not arise when the addictive oncogene is
mutated or translocated, as in the case of EGFR-mutant and ALK-
translocated lung cancers. This fundamental difference would
appear to contribute to the differential efficacy of these drugs
compared with HER2 inhibitors, and analogous situations may
arise in other cancers addicted to oncogenes that are activated
by amplification.
Materials and Methods
Cell Lines. The cell lines in this study were from the Massachusetts General
Hospital. SKBR3, BT-474, MDA-MB-231, MDA-MB-468, and BT-549 cells were
grown in DMEM/F12 (HyClone Laboratories, Inc.) with 10% FBS in the presence
of 1 μg/mL penicillin and streptomycin. MDA-MB-361, MDA-MB-453, HCC-
1419, UACC-893, HCC-1395, HCC-1937, and HCC-38 cells were cultured in
RPMI with 10% FBS in the presence of 1 μg/mL penicillin and streptomycin.
UACC-812, CAL-120, MCF-7, and 293T cells were cultured in DMEM with 10%
FBS in the presence of antibiotics. EFM-192A cells were grown in RPMI with
20% FBS in the presence of 1 μg/mL penicillin and streptomycin.
Reagents and Antibodies. The following drugs were kindly provided by
Abbvie: venetoclax, A1210477, and A1331852. The following drugs were
purchased: S63845 for in vitro and in vivo studies (S-63845; Chemietek),
Lapatinib Ditosylate (Tykerb) for in vitro and in vivo studies (M1802; Abmole),
and Fulvestrant (S1191; Selleckchem).
The antibodies used in this study (clone/cat. no.) were as follows: Anti-Bak
(Ab-1 clone for IP) (AM03; EMD Millipore), anti-BAX (6A7 clone for IP) (sc-
23959; Santa Cruz), anti-BAX (N-20 clone) (sc-493; Santa Cruz), anti-Bak
(3814S; Cell Signaling), anti-Bim (C34C5) (2933S; Cell Signaling), anti-Noxa
(D8L7U) (14766S; Cell Signaling), anti–Bcl-2 (D55G8) (Human Specific) (4223S;
Cell Signaling), anti-Cleaved PARP (Asp214) (D64E10) (5625S; Cell Signaling),
anti-GAPDH (6C5) (sc-32233; Santa Cruz), anti-HER2/ErbB2 (29D8) (2165S;
Cell Signaling), anti–MCL-1 (S-19) (sc-819; Santa Cruz), anti–BCL-xL (54H6)
(2764S; Cell Signaling), 4E-BP1 (53H11) (9644S; Cell Signaling), phospho-4E-
BP1 (Thr37/46) (236B4) (2855S; Cell Signaling), anti–Phospho-S6 Ribosomal
Protein (Ser240/244) (D68F8) (5364S; Cell Signaling), anti–Phospho-Akt
(Thr308) (244F9) (4056S; Cell Signaling), anti-ERα (D8H8) (8644S; Cell Sig-
naling), anti–Phospho-HER2/ErbB2 (Tyr1248) (2247S; Cell Signaling), anti-Akt
(C67E7) (4691S; Cell Signaling), anti-cleaved Caspase-3 (Asp175) (5A1E; Cell
Signaling), Normal Rabbit IgG for IP (sc-2027; Santa Cruz), and Normal
Mouse IgG for IP (sc-2025; Santa Cruz).
All mouse experiments were approved and performed in accordance with
the Institutional Animal Care and Use Committee at Virginia Commonwealth
University (VCU).
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